Drug intelligence / Profile preview

C. difficile vaccine formulation 2

Development stage: Unknown
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

C. difficile vaccine formulation 2 is one of three new toxoid-based vaccine formulations developed by Pfizer to prevent severe diarrhea caused by *Clostridioides difficile* (C. diff). It is administered via intramuscular injection and is currently being evaluated in a Phase 1/2 clinical study to assess its safety, tolerability, immunogenicity, and immunopersistence in healthy adults aged 65 to 84 years who have not previously had a C. diff infection or received a C. diff vaccine or monoclonal antibody therapy.

Targets

TcdA (Clostridioides difficile toxin A)TcdB (Clostridioides difficile large clostridial toxin family)

Beyond the preview

Go deeper on C. difficile vaccine formulation 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C. difficile vaccine formulation 2.

Explore the full profile